MX2022010816A - Composiciones y métodos para evaluar la eficacia de los inhibidores de los transportadores de neurotransmisores. - Google Patents
Composiciones y métodos para evaluar la eficacia de los inhibidores de los transportadores de neurotransmisores.Info
- Publication number
- MX2022010816A MX2022010816A MX2022010816A MX2022010816A MX2022010816A MX 2022010816 A MX2022010816 A MX 2022010816A MX 2022010816 A MX2022010816 A MX 2022010816A MX 2022010816 A MX2022010816 A MX 2022010816A MX 2022010816 A MX2022010816 A MX 2022010816A
- Authority
- MX
- Mexico
- Prior art keywords
- efficacy
- inhibitors
- methods
- assessing
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986603P | 2020-03-06 | 2020-03-06 | |
| PCT/US2021/019265 WO2021178166A1 (en) | 2020-03-06 | 2021-02-23 | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010816A true MX2022010816A (es) | 2022-12-13 |
Family
ID=77613738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010816A MX2022010816A (es) | 2020-03-06 | 2021-02-23 | Composiciones y métodos para evaluar la eficacia de los inhibidores de los transportadores de neurotransmisores. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12612661B2 (https=) |
| EP (1) | EP4106872A4 (https=) |
| JP (1) | JP2023515665A (https=) |
| KR (1) | KR20230005816A (https=) |
| CN (1) | CN115515680A (https=) |
| AR (1) | AR121515A1 (https=) |
| AU (1) | AU2021231683A1 (https=) |
| BR (1) | BR112022017770A2 (https=) |
| CA (1) | CA3174572A1 (https=) |
| IL (1) | IL296168A (https=) |
| MX (1) | MX2022010816A (https=) |
| TW (1) | TW202146660A (https=) |
| WO (1) | WO2021178166A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000019303A1 (it) * | 2020-08-05 | 2022-02-05 | Univ Degli Studi Di Brescia | Analoghi strutturali del metilfenidato come agenti disease-modifying della malattia di parkinson |
| CN114848835B (zh) * | 2022-03-22 | 2023-08-25 | 暨南大学 | 塞来昔布的聚乙二醇修饰及连接叶酸基团的靶向药物分子及制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6945457B1 (en) * | 1996-05-10 | 2005-09-20 | Transaction Holdings Ltd. L.L.C. | Automated transaction machine |
| JP4198582B2 (ja) * | 2003-12-02 | 2008-12-17 | 独立行政法人科学技術振興機構 | タンタルオキシナイトライド酸素還元電極触媒 |
| WO2007128884A1 (en) * | 2006-05-09 | 2007-11-15 | Oy Jurilab Ltd | Novel genes and markers in type 2 diabetes and obesity |
| US20080299125A1 (en) | 2006-06-05 | 2008-12-04 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
| WO2008065544A2 (en) | 2006-09-11 | 2008-06-05 | Mcgill University | Genetic predictors of risk for type 2 diabetes mellitus |
| EP2243834A1 (en) | 2007-03-05 | 2010-10-27 | Cancer Care Ontario | Assessment of risk for colorectal cancer |
| US20170029892A1 (en) | 2009-05-29 | 2017-02-02 | Jay L. Lombard | Methods and compositions for the treatment of post-traumatic stress disorder |
| US8355927B2 (en) * | 2010-11-05 | 2013-01-15 | Genomind, Llc | Neuropsychiatric test reports |
| EP2707498B1 (en) | 2011-01-31 | 2018-01-17 | Denovo Biomarkers Inc. | Method for discovering pharmacogenomic biomarkers |
| WO2012156515A1 (en) * | 2011-05-18 | 2012-11-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | Molecular analysis of acute myeloid leukemia |
| CA2838207A1 (en) | 2011-06-08 | 2012-12-13 | Denovo Biopharma (Hangzhou) Ltd. Co. | Methods and compositions of predicting activity of retinoid x receptor modulator |
| US20140274764A1 (en) | 2013-03-15 | 2014-09-18 | Pathway Genomics Corporation | Method and system to predict response to treatments for mental disorders |
| US20170253928A1 (en) | 2013-03-15 | 2017-09-07 | Pathway Genomics Corporation | Method and system to predict response to treatments for mental disorders |
| TR201907106T4 (tr) | 2014-03-14 | 2019-06-21 | Caredx Inc | Bir transplant alıcısında immünosüpresif terapileri izleme yöntemleri. |
-
2021
- 2021-02-23 CA CA3174572A patent/CA3174572A1/en active Pending
- 2021-02-23 KR KR1020227034374A patent/KR20230005816A/ko active Pending
- 2021-02-23 EP EP21764344.4A patent/EP4106872A4/en active Pending
- 2021-02-23 BR BR112022017770A patent/BR112022017770A2/pt unknown
- 2021-02-23 AU AU2021231683A patent/AU2021231683A1/en active Pending
- 2021-02-23 JP JP2022552541A patent/JP2023515665A/ja active Pending
- 2021-02-23 WO PCT/US2021/019265 patent/WO2021178166A1/en not_active Ceased
- 2021-02-23 IL IL296168A patent/IL296168A/en unknown
- 2021-02-23 US US17/905,511 patent/US12612661B2/en active Active
- 2021-02-23 MX MX2022010816A patent/MX2022010816A/es unknown
- 2021-02-23 CN CN202180031602.1A patent/CN115515680A/zh active Pending
- 2021-03-05 AR ARP210100576A patent/AR121515A1/es unknown
- 2021-03-05 TW TW110107927A patent/TW202146660A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12612661B2 (en) | 2026-04-28 |
| CN115515680A (zh) | 2022-12-23 |
| WO2021178166A1 (en) | 2021-09-10 |
| CA3174572A1 (en) | 2021-09-10 |
| US20230193388A1 (en) | 2023-06-22 |
| BR112022017770A2 (pt) | 2022-11-29 |
| JP2023515665A (ja) | 2023-04-13 |
| TW202146660A (zh) | 2021-12-16 |
| EP4106872A4 (en) | 2024-04-10 |
| EP4106872A1 (en) | 2022-12-28 |
| KR20230005816A (ko) | 2023-01-10 |
| IL296168A (en) | 2022-11-01 |
| AU2021231683A1 (en) | 2022-09-22 |
| AR121515A1 (es) | 2022-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sujana et al. | Whistleblowing system, competence, morality, and internal control system against fraud prevention on village financial management in Denpasar | |
| WO2020243415A3 (en) | Tead inhibitors and uses thereof | |
| EP4357783A3 (en) | Highly sensitive system and methods for analysis of troponin | |
| BR112023021561A2 (pt) | Compostos de carbóxi-benzimidazol moduladores de glp-1r | |
| PH12014501106B1 (en) | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases | |
| MX2022010816A (es) | Composiciones y métodos para evaluar la eficacia de los inhibidores de los transportadores de neurotransmisores. | |
| CL2022001825A1 (es) | Inhibidores de sarm1 | |
| PH12021500008A1 (en) | Transglutaminase 2 (tg2) inhibitors | |
| BR112022005711A2 (pt) | Métodos e composições para tratar uma doença ou transtorno | |
| EP4588512A3 (en) | Methods and compositions for treating a bleeding event in a subject having hemophilia | |
| MX2023013173A (es) | Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos. | |
| WO2020160291A3 (en) | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF | |
| WO2020239895A3 (en) | Detection of colorectal cancer | |
| CR20140422A (es) | Composiciones de enzima digestiva estable | |
| PH12016500302A1 (en) | Compositions and method for treating complement-associated conditions | |
| GT201000088A (es) | 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa | |
| BR112019002679A2 (pt) | redução de sinal de ácidos nucleicos contaminantes | |
| WO2021092145A8 (en) | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases | |
| BR112021016783A2 (pt) | Composições e métodos para tratar laminopatias | |
| FR3045834B1 (fr) | Diluant de reactifs pour immunoessai | |
| MX2024004993A (es) | Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| BR112019021352A8 (pt) | Método para determinar e mitigar o risco de formação de cera de uma composição de hidrocarboneto, método para reduzir os riscos de formação de cera e sistema para uso de análise preditiva no gerenciamento de um processamento de hidrocarbonetos para determinar e mitigar a formação de cera | |
| WO2007100777A3 (en) | Methods for the treatment of adhd and related disorders | |
| WO2022204581A3 (en) | Tgf-beta inhibitors and use thereof | |
| ZA202303864B (en) | Microbiome signature for the charcatrization of skin types |